Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Hepatitis C
Interventions: Daclatasvir, Sofosbuvir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more

Conditions: Hepatitis C, Medication Adherence
Interventions: HepCure ToolKit, AdhereTech Active Features, AdhereTech Passive Monitoring; Other · Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 89 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 58
States / cities: Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more

Conditions: Hepatitis C Virus
Interventions: Sofosbuvir, Placebo to match sofosbuvir, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more

Conditions: Hepatitis C, Chronic
Interventions: IdB 1016; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatitis C, Depression
Interventions: Depression collaborative care model; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Little Rock, Arkansas • West Los Angeles, California • St Louis, Missouri + 1 more

Conditions: HCV Infection
Interventions: GS-9450, GS-9450 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Anaheim, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Conditions: Hepatitis C, Chronic
Interventions: glecaprevir (300mg)/pibrentasvir (120mg); Drug
Lead sponsor: Kirby Institute; Government
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more

Conditions: Hepatitis C, Pregnancy
Interventions: ledipasvir/sofosbuvir; Drug
Lead sponsor: Catherine Chappell; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatitis C
Interventions: peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 5 more

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Hepatitis C
Interventions: TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more

Conditions: Kidney Failure, Kidney Diseases, Hepatitis C
Interventions: glecaprevir/pibrentasvir tablets; Drug
Lead sponsor: Raymond T. Chung, MD; Other
Eligibility: 30 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: Patients receiving Sof/Vel (Epclusa) and Navigation services; Drug
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Hepatitis C Infection in HIV Infected Persons, HIV Infections
Interventions: Peginterferon a-2a plus Ribavirin; Drug
Lead sponsor: Hepatitis Resource Network; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Sorafenib+YIV-906, Sorafenib+placebo; Drug
Lead sponsor: Yiviva Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Flushing, New York • Lake Success, New York • New York, New York + 1 more

Conditions: Hepatitis C, Chronic
Interventions: ISIS 14803; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Chronic Hepatitis C
Interventions: ANZ-521, Placebo; Drug
Lead sponsor: Anza Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Anaheim, California • San Antonio, Texas

Conditions: Hepatitis c
Interventions: Leap-c group intervention; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, RO5190591, RO5466731, ribavirin [Copegus], ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: La Jolla, California • Englewood, Colorado • South Miami, Florida + 11 more

Conditions: Hepatitis C Virus
Interventions: Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Hepatitis C Virus Infection
Interventions: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more

Search by objective public record fields.

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Evaluation of HepCure Toolkit to Improve Harvoni Adherence

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

IdB 1016 Treatment for Hepatitis C Disease

Hepatitis C Translating Initiatives for Depression Into Effective Solutions

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

Study of Hepatitis C Treatment During Pregnancy

Hepatitis C Antiviral Resistance in African-Americans

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

Curing HCV in Incarcerated Patients

HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection